The −202 A Allele of Insulin-Like Growth Factor Binding Protein-3 (IGFBP3) Promoter Polymorphism Is Associated with Higher IGFBP-3 Serum Levels and Better Growth Response to Growth Hormone Treatment in Patients with Severe Growth Hormone Deficiency

• DOI: 10.1210/jc.2008-1608
• Publication Date: 2008-11-05T02:15:08Z
• Authors: Everlayny Fiorot ...; Sonir R. Antonini; Gil Guerra-Junior; Berenice Bilharin...; Ivo J. P. Arnhold; Alexander A. L. J...
• Keywords: IGFBP3

Genetic factors that influence the response to recombinant human GH (rhGH) therapy remain mostly unknown. To date, only receptor gene has been investigated.The aim of study was assess a polymorphism in IGF-binding protein-3 (IGFBP-3) promoter region (-202 A/C) on circulating IGFBP-3 levels and growth rhGH children with deficiency (GHD).-202 A/C IGFBP3 genotyping (rs2854744) correlated data 71 severe GHD who remained prepubertal during first year treatment.We measured velocity (GV) treatment.Clinical laboratory at start treatment were indistinguishable among patients different -202 genotypes. Despite similar doses, homozygous for A allele presented higher sd score mean GV than AC or CC genotypes (first GV, AA = 13.0 +/- 2.1 cm/yr, 11.4 2.5 10.8 1.9 cm/yr; P 0.016). Multiple linear regression analyses demonstrated genotype independent other variables.The is associated increased children.